Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTED.L Regulatory News (TED)

  • There is currently no data for TED

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New testing facility

3 Jul 2007 07:01

Tepnel Life Sciences PLC03 July 2007 PRESS RELEASE Tepnel Life Sciences announces completion of its pharmaceutical testing facility in Scotland 3 July 2007: Tepnel Life Sciences (AIM: TED), the international MolecularDiagnostics and Research Products and Services group, today announced it hascompleted Phase I of its new pharmaceutical testing facility based inLivingston, Scotland. Construction commenced on the state-of-the-art laboratory in July 2006 andoperational activity will begin in July this year. The facility will house 47staff to be relocated from Tepnel's Edinburgh and Glasgow operations. It willaccommodate Tepnel's protein analysis and genomic testing laboratories as wellas the Company's analytical chemistry, bioanalysis and microbiology facilities. Tepnel will initially occupy 14,000sq ft and Phase II development of theremaining 4000sq ft will begin in September. This 4000sq ft will house Tepnel'sMolecular Services group which will provide genotyping, whole genomeamplification, sequencing and gene expression services. Tepnel plans to establish a clinical genotyping operation at Livingston whilecontinuing its successful development of specialised products and services inhigh growth areas such as pharmacogenomics, new generations of vaccines and therapidly evolving therapeutic protein market. Tepnel's Chief Executive Officer, Ben Matzilevich, said: "Our new laboratorieshave been built on time and to budget. The facility is an important component ofour long-term strategy that will allow Tepnel to extend its market presence inthe fast-growing biological medicines sector. Continuity of service toTepnel's customers will be maintained throughout the transition to the newlocation." Tepnel's new Livingston facility was part funded by Scottish Enterprise,Edinburgh and Lothian. -Ends- For further information: Tepnel Life Sciences plc Ben Matzilevich, CEOCarol SmithTel: 0161 946 2200 Capital MS&L Mary Clark or Catie CorcoranTel: +44 20 7307 5330 Seymour Pierce LimitedMark PercyTel: +44 20 7107 8000 Notes to Editors: About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. Tepnel provides test kits, reagents and services to two highly synergisticmarkets, these being Molecular Diagnostics and Biomedical Research. The company's strategy has been to identify high growth niche opportunitieswithin these multi-billion pound markets. Tepnel focuses on these opportunitieswith internally developed products, patents, expertise and know-how as well asstrategic acquisitions, to develop a leadership position within these definedmarket segments. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Jun 20228:47 amRNSForm 8.5 (EPT/RI)
6th Jun 20228:29 amRNSForm 8.3 - Ted Baker PLC
1st Jun 20221:58 pmRNSForm 8.3 - Ted Baker plc
1st Jun 20221:45 pmRNSTotal Voting Rights
1st Jun 20229:30 amRNSForm 8.5 (EPT/RI)
1st Jun 20228:34 amRNSForm 8.3 - TED BAKER PLC
31st May 20223:21 pmRNSForm 8.3 - Ted Baker Plc
31st May 202212:51 pmRNSForm 8.3 - Ted Baker plc
31st May 20229:29 amRNSForm 8.5 (EPT/RI)
31st May 20228:47 amRNSForm 8.3 - TED BAKER PLC
31st May 20228:15 amRNSForm 8.5 (EPT/RI)
30th May 20222:21 pmRNSForm 8.3 - Ted Baker plc
30th May 20222:08 pmRNSForm 8.3 - Ted Baker PLC
30th May 202211:43 amRNSForm 8.5 (EPT/RI)
30th May 20229:47 amRNSForm 8.3 - Ted Baker PLC
30th May 20228:54 amRNSForm 8.5 (EPT/RI)
27th May 20223:15 pmRNSForm 8.3 - Ted Baker plc
27th May 202212:41 pmRNSForm 8.3 - Ted Baker plc
27th May 20229:51 amRNSForm 8.3 - Ted Baker PLC
27th May 20228:59 amRNSForm 8.5 (EPT/RI)
27th May 20228:31 amRNSForm 8.5 (EPT/RI)
26th May 20222:36 pmRNSForm 8.3 - Ted Baker plc
26th May 202210:19 amRNSPreliminary Results and Q1 trading update
26th May 20229:42 amRNSForm 8.5 (EPT/RI)
26th May 20228:24 amRNSForm 8.3 - TED BAKER PLC
26th May 20227:58 amRNSTiming of Full Year Results
25th May 20223:10 pmRNSForm 8.3 -TED BAKER PLC
25th May 202211:01 amRNSForm 8.5 (EPT/RI)
25th May 20229:56 amRNSForm 8.5 (EPT/RI)
25th May 20229:24 amRNSForm 8.3 - Ted Baker PLC
24th May 20223:22 pmRNSForm 8.3 - Ted Baker Plc
24th May 20221:59 pmRNSForm 8.3 - Ted Baker plc
24th May 202210:21 amRNSForm 8.3 - Ted Baker PLC
24th May 20229:19 amRNSForm 8.5 (EPT/RI)
24th May 20228:25 amRNSForm 8.3 - TED BAKER PLC
23rd May 20223:55 pmRNSForm 8.3 - TED BAKER PLC
23rd May 20223:19 pmRNSForm 8.3 - Ted Baker plc
23rd May 20229:39 amRNSForm 8.3 - Ted Baker PLC
23rd May 20229:22 amRNSForm 8.5 (EPT/RI)
23rd May 20227:00 amRNSUpdate on Formal Sale Process
20th May 20222:01 pmRNSForm 8.3 - TED BAKER PLC
20th May 20229:41 amRNSForm 8.3 - Ted Baker PLC
20th May 20229:09 amRNSForm 8.5 (EPT/RI)
20th May 20228:48 amRNSForm 8.5 (EPT/RI)
19th May 20221:40 pmRNSForm 8.3 - Ted Baker plc
19th May 202212:05 pmRNSForm 8.5 (EPT/RI)
19th May 202211:30 amRNSForm 8.3 - Ted Baker PLC
19th May 20229:58 amBUSForm 8.3 - TED BAKER PLC
18th May 202211:55 amRNSForm 8.3 - Ted Baker plc
18th May 202210:11 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.